Letrozole; Ribociclib Succinate Patent Expiration

Letrozole; Ribociclib Succinate is Used for the initial endocrine-based therapy in adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer. It was first introduced by Novartis Pharmaceuticals Corp in its drug Kisqali Femara Co-Pack (Copackaged) on May 4, 2017.


Letrozole; Ribociclib Succinate Patents

Given below is the list of patents protecting Letrozole; Ribociclib Succinate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Kisqali Femara Co-pack (copackaged) US10799506 Ribociclib tablet Apr 14, 2036 Novartis
Kisqali Femara Co-pack (copackaged) US8324225 Pyrrolopyrimidine compounds and their uses Jun 17, 2028 Novartis
Kisqali Femara Co-pack (copackaged) US8415355 Pyrrolopyrimidine compounds and their uses Mar 13, 2031 Novartis
Kisqali Femara Co-pack (copackaged) US8685980 Pyrrolopyrimidine compounds and their uses May 25, 2030 Novartis
Kisqali Femara Co-pack (copackaged) US8962630 Pyrrolopyrimidine compounds and their uses Dec 09, 2029 Novartis
Kisqali Femara Co-pack (copackaged) US9193732 Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof Nov 09, 2031 Novartis
Kisqali Femara Co-pack (copackaged) US9416136 Pyrrolopyrimidine compounds and their uses Aug 20, 2029 Novartis
Kisqali Femara Co-pack (copackaged) US9868739 Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof Nov 09, 2031 Novartis


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳